Aclaris Therapeutics, Inc.ACRSNASDAQ
Loading
ACRS Revenue Growth (YoY Quarterly)•-85.94%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
-85.94%
-61.8pp
+0.00%
-42.5pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+28.71%
-43.1pp
+28.71%
-43.1pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -47.58% | -39.32% | -35.76% | -24.09% | -85.94% |
| Gross Profit Growth | -100.81% | +70.07% | -108.52% | +42.47% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +34.49% | +72.20% | +71.94% | +71.78% | +28.71% |
| Weighted Average Shares Diluted Growth | +34.49% | +72.20% | +71.94% | +71.78% | +28.71% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -149.69% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -149.80% | +0.00% |
| Receivables Growth | +6.71% | -32.98% | -40.31% | +1264.43% | +1650.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +11.61% | +13.80% | +17.43% | -3.76% | -27.17% |
| Book Value per Share Growth | -26.41% | -41.09% | -42.75% | -46.28% | -48.51% |
| Debt Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | -66.13% | +17.66% | +30.71% | +118.74% | +83.74% |
| SG&A Expenses Growth | -39.69% | -10.30% | +15.78% | -13.83% | +12.56% |
1 / 4